Pimozide for schizophrenia or related psychoses (Q24244147)

PubMed

PubMed publication ID

17636692

9 December 2023

Tom McMonagle

series ordinal

2

author given names

T

author last names

McMonagle

1 reference

PubMed

PubMed publication ID

17636692

Cochrane Database of Systematic Reviews

9 December 2023

publication date

18 July 2007

0 references

published in

0 references

cites work

Pimozide in the treatment of newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Token Economy, Pimozide and Chronic Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

An International Double‐Blind Clinical Evaluation of Pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Short-term outcome in trial entrants and trial eligible patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Pimozide in acute schizophrenia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Psychopharmacology for dermatologic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Psychopharmacologic treatment of negative schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Lack of gender differences in neuroleptic response in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

A comparative double-blind trial of pimozide in stress-induced psychic and functional disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Impact of substance abuse on the course and outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Delusional disorder (paranoia)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: Pimozide versus fluphenazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

A pilot study of pimozide in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozide vs. fluphenazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Activity in chronic schizophrenic patients: comparison of pimozide with fluphenazine in a double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Therapeutic measures in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

NATURE AND TREATMENT OF DELUSIONAL PARASITOSIS: A DIFFERENT EXPERIENCE IN INDIA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

A controlled trial of pimozide and trifluoperazine in chronic schizophrenic syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Comparison of pimozide and chlorpromazine in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The Scottish First Episode Schizophrenia Study. III. Cognitive performance. The Scottish Schizophrenia Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

The Scottish First Episode Schizophrenia Study V. One-year follow-up. The Scottish Schizophrenia Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021

Post-mortem antipsychotic drug concentrations and unexplained deaths

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949.PUB2

7 January 2021